Key Takeaways ABBV offset Humira's LOE as Skyrizi & Rinvoq delivered $18.5B combined sales in the first nine months of 2025.MRK's Keytruda drove growth with $23.3B in sales in the first nine months of 2025.ABBV shares rose 26.6% over the past year as ex-Humira drugs fueled renewed revenue growth.Merck (MRK) and AbbVie (ABBV) are leading pharmaceutical players with entrenched franchises in oncology and immunology. Beyond these core areas, AbbVie has built a presence in aesthetics, neuroscience and eye care, ...